首页 > 最新文献

Lancet Psychiatry最新文献

英文 中文
Etomidate misuse: a digital era threat to youth and a call for anticipatory control 滥用依托咪酯:数字时代对青年的威胁和对预期控制的呼吁
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-16 DOI: 10.1016/s2215-0366(25)00267-6
Teng Gao, Meng Jin, Rowalt Alibudbud, Sawitri Assanangkornchai, Yankun Sun, Lin Lu
No Abstract
没有抽象的
{"title":"Etomidate misuse: a digital era threat to youth and a call for anticipatory control","authors":"Teng Gao, Meng Jin, Rowalt Alibudbud, Sawitri Assanangkornchai, Yankun Sun, Lin Lu","doi":"10.1016/s2215-0366(25)00267-6","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00267-6","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"28 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Weight management in severe mental illness: bridging the gap between guidelines and primary care 严重精神疾病的体重管理:弥合指南与初级保健之间的差距
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-16 DOI: 10.1016/s2215-0366(25)00265-2
Sri Mahavir Agarwal, Nicolette Stogios, Margaret Hahn
No Abstract
没有抽象的
{"title":"Weight management in severe mental illness: bridging the gap between guidelines and primary care","authors":"Sri Mahavir Agarwal, Nicolette Stogios, Margaret Hahn","doi":"10.1016/s2215-0366(25)00265-2","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00265-2","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"21 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Running a psychiatric ward in times of war 在战争时期经营精神病院
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-16 DOI: 10.1016/s2215-0366(25)00264-0
Mark Weiser, Itai Pessach, Amitai Ziv
No Abstract
没有抽象的
{"title":"Running a psychiatric ward in times of war","authors":"Mark Weiser, Itai Pessach, Amitai Ziv","doi":"10.1016/s2215-0366(25)00264-0","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00264-0","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"29 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychiatric care in Gaza: prescribing amid systematic health care collapse 加沙的精神科护理:在系统性卫生保健崩溃的情况下开处方
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-16 DOI: 10.1016/s2215-0366(25)00270-6
Ahmed Alhaj
No Abstract
没有抽象的
{"title":"Psychiatric care in Gaza: prescribing amid systematic health care collapse","authors":"Ahmed Alhaj","doi":"10.1016/s2215-0366(25)00270-6","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00270-6","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"52 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Respiratory diseases in individuals with severe mental illness 严重精神疾病患者的呼吸系统疾病
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-16 DOI: 10.1016/s2215-0366(25)00279-2
Ole Köhler-Forsberg, Oleguer Plana-Ripoll, Nina Friis Bak Fuglsang
No Abstract
没有抽象的
{"title":"Respiratory diseases in individuals with severe mental illness","authors":"Ole Köhler-Forsberg, Oleguer Plana-Ripoll, Nina Friis Bak Fuglsang","doi":"10.1016/s2215-0366(25)00279-2","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00279-2","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"40 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines 初级保健中痴呆患者的抗精神病药物处方:一项调查英国临床指南剂量和持续时间依从性的队列研究
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-16 DOI: 10.1016/s2215-0366(25)00261-5
Holly Christina Smith, Irene Petersen, Joseph F Hayes, Kelvin P Jordan, Magnus Boman, Sube Banerjee, Kate Walters, Claudia Cooper, Juan Carlos Bazo-Alvarez

Background

In the UK, it is recommended by the National Institute for Health and Care Excellence (NICE) that if antipsychotics are initiated in people living with dementia, treatment should be at the lowest dose for the shortest time possible (1–3 months). In this study, we aimed to investigate how dose and duration of antipsychotic medication adhere to UK clinical guidelines and explore treatment restart details in those who stop treatment.

Methods

We did a retrospective cohort study using longitudinal UK primary care data from the IQVIA Medical Research Database. We included people living with dementia aged 60–85 years who received their first antipsychotic prescription between Jan 1, 2000, and Dec 31, 2023. Individuals with any previous antipsychotic prescriptions in their records more than 1 year before a dementia diagnosis and those who had missing social deprivation information were excluded from the study. Duration of first and subsequent antipsychotic treatment episodes, medication dosage, and treatment discontinuation and reinitiation rates were investigated. Duration and discontinuation were defined by grouping consecutive prescriptions into treatment episodes using the waiting time distribution method (80% inter-arrival density, 59 days). Daily doses were derived from strength and frequency information and categorised as low or moderate or high based on established minimum effective dose equivalences. People with lived experience of dementia care contributed throughout this project, shaping the research question and advising on interpretation and dissemination strategies.

Findings

In our dataset search, we identified 108 910 people with a record indicating dementia at any time. In total, 99 091 cases were excluded (ie, individuals with no antipsychotic prescription between the ages of 60 and 85 years between 2000 and 2023, a previous history of antipsychotics, missing deprivation information, or only one eligible prescription). We included 9819 people living with dementia aged 60–85 years who received their first antipsychotic prescription between 2000 and 2023 in the study. 5310 (54·1%) were female and 4509 (45·9%) were male, with a mean age of 77·1 years (SD 5·6 years), and ethnicity data were not available. The first treatment episode lasted a median of 7 months (IQR 6·6–8·7), exceeding NICE guidelines of 1–3 months and 18·1% [95% CI 17·4–18·9]) were initiated on a prescription above the minimum effective dose (ie, low dose). Of the 1781 participants who started on a moderate or high dose, 519 (29·1%) had a moderate or high dose in all quarters of the first year of treatment. 1 year after treatment initiation, 5136 (78·3%) of 6559 eligible individuals remained on medication (48·9% [95% CI 47·7–50·1] on low dose, 14·8% [13·9–15·6] on moderate or high dose of haloperidol, olanzapine, quetiapine or risperidone; and 14·6% [13·8–15·5] on other antipsychotics). Of the 5547 individuals eligible to restart treatment af
背景:在英国,国家健康与护理卓越研究所(NICE)建议,如果对痴呆症患者开始使用抗精神病药物,应在尽可能短的时间内(1-3个月)使用最低剂量的治疗。在这项研究中,我们旨在调查抗精神病药物的剂量和持续时间如何遵守英国临床指南,并探索停止治疗的患者重新开始治疗的细节。方法:我们使用来自IQVIA医学研究数据库的纵向英国初级保健数据进行回顾性队列研究。我们纳入了在2000年1月1日至2023年12月31日期间首次服用抗精神病药物的60-85岁痴呆症患者。在痴呆症诊断前一年以上的记录中有任何抗精神病药物处方的人以及那些缺少社会剥夺信息的人被排除在研究之外。研究了首次和后续抗精神病药物治疗的持续时间、药物剂量、停药和重新开始治疗的比率。使用等待时间分布方法(80%间隔到达密度,59天)将连续处方分组为治疗发作,定义持续时间和停药时间。日剂量根据强度和频率信息得出,并根据确定的最小有效剂量当量分为低、中或高。有痴呆症护理生活经验的人在整个项目中做出了贡献,形成了研究问题,并就解释和传播策略提供了建议。在我们的数据集搜索中,我们确定了108910人在任何时候都有痴呆症的记录。总共有99 091例病例被排除在外(即,2000年至2023年期间60至85岁之间没有抗精神病药物处方,既往有抗精神病药物史,缺少剥夺信息,或只有一个符合条件的处方)。我们纳入了9819名年龄在60-85岁之间的痴呆症患者,他们在2000年至2023年期间接受了第一次抗精神病药物处方。女性5310例(54.1%),男性4509例(45.9%),平均年龄77.1岁(SD 5.6岁),族裔数据不详。第一次治疗持续的中位时间为7个月(IQR为6.6 - 8.7),超过NICE指南的1-3个月,18.1% [95% CI为17.4 - 18.9]的患者开始使用的处方高于最低有效剂量(即低剂量)。在1781名开始使用中剂量或高剂量的参与者中,519名(29.1%)在第一年治疗的所有季度中都使用中剂量或高剂量。在开始治疗1年后,6559名符合条件的患者中有5136人(78.3%)仍在服药(48.9% [95% CI 47.7 - 50.1]服用低剂量氟哌啶醇、奥氮平、喹硫平或利培酮服用中剂量或高剂量氟哌啶醇、奥氮平、喹硫平或利培酮服用14.8%[13.9 - 15.6],14.6%[13.8 - 15.5]服用其他抗精神病药物)。在初始停药后符合重新开始治疗条件的5547例患者中,3106例(56%)重新开始治疗,中位治疗持续时间为2.6个月(IQR 0 - 9.0)。这项研究强调了痴呆症的抗精神病药物处方在持续时间和剂量上与目前NICE指南的不一致。一半以上停止治疗的患者随后又重新开始治疗。这些发现强调了临床指南和现实世界处方之间的持续差距,强调了优先考虑安全性和以人为本的痴呆症护理的干预措施的必要性。资助国家卫生和保健研究所初级保健研究学校。
{"title":"Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines","authors":"Holly Christina Smith, Irene Petersen, Joseph F Hayes, Kelvin P Jordan, Magnus Boman, Sube Banerjee, Kate Walters, Claudia Cooper, Juan Carlos Bazo-Alvarez","doi":"10.1016/s2215-0366(25)00261-5","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00261-5","url":null,"abstract":"<h3>Background</h3>In the UK, it is recommended by the National Institute for Health and Care Excellence (NICE) that if antipsychotics are initiated in people living with dementia, treatment should be at the lowest dose for the shortest time possible (1–3 months). In this study, we aimed to investigate how dose and duration of antipsychotic medication adhere to UK clinical guidelines and explore treatment restart details in those who stop treatment.<h3>Methods</h3>We did a retrospective cohort study using longitudinal UK primary care data from the IQVIA Medical Research Database. We included people living with dementia aged 60–85 years who received their first antipsychotic prescription between Jan 1, 2000, and Dec 31, 2023. Individuals with any previous antipsychotic prescriptions in their records more than 1 year before a dementia diagnosis and those who had missing social deprivation information were excluded from the study. Duration of first and subsequent antipsychotic treatment episodes, medication dosage, and treatment discontinuation and reinitiation rates were investigated. Duration and discontinuation were defined by grouping consecutive prescriptions into treatment episodes using the waiting time distribution method (80% inter-arrival density, 59 days). Daily doses were derived from strength and frequency information and categorised as low or moderate or high based on established minimum effective dose equivalences. People with lived experience of dementia care contributed throughout this project, shaping the research question and advising on interpretation and dissemination strategies.<h3>Findings</h3>In our dataset search, we identified 108 910 people with a record indicating dementia at any time. In total, 99 091 cases were excluded (ie, individuals with no antipsychotic prescription between the ages of 60 and 85 years between 2000 and 2023, a previous history of antipsychotics, missing deprivation information, or only one eligible prescription). We included 9819 people living with dementia aged 60–85 years who received their first antipsychotic prescription between 2000 and 2023 in the study. 5310 (54·1%) were female and 4509 (45·9%) were male, with a mean age of 77·1 years (SD 5·6 years), and ethnicity data were not available. The first treatment episode lasted a median of 7 months (IQR 6·6–8·7), exceeding NICE guidelines of 1–3 months and 18·1% [95% CI 17·4–18·9]) were initiated on a prescription above the minimum effective dose (ie, low dose). Of the 1781 participants who started on a moderate or high dose, 519 (29·1%) had a moderate or high dose in all quarters of the first year of treatment. 1 year after treatment initiation, 5136 (78·3%) of 6559 eligible individuals remained on medication (48·9% [95% CI 47·7–50·1] on low dose, 14·8% [13·9–15·6] on moderate or high dose of haloperidol, olanzapine, quetiapine or risperidone; and 14·6% [13·8–15·5] on other antipsychotics). Of the 5547 individuals eligible to restart treatment af","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"71 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mortality from respiratory diseases in individuals with severe mental illness: a large-scale systematic review and meta-analysis of pooled and specific diagnoses 严重精神疾病患者呼吸系统疾病的死亡率:一项大规模的系统回顾和汇总和特定诊断的荟萃分析
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-16 DOI: 10.1016/s2215-0366(25)00262-7
David Laguna-Muñoz, María P Pata, Ana Jiménez-Peinado, María José Jaén-Moreno, Cristina Camacho-Rodríguez, Gloria Isabel del Pozo, Eduard Vieta, Christoph U Correll, Marco Solmi, Javier Caballero-Villarraso, María Isabel Alarcón-Laguna, Fernando Sarramea
<h3>Background</h3>People with severe mental illness have a 10–20 year reduced life-expectancy compared with the general population. Respiratory diseases are a main cause of this premature mortality, but no comprehensive meta-analysis of overall and respiratory cause-specific mortality risk in this population exists. We aimed to evaluate the mortality from specific respiratory diseases for people with pooled severe mental illnesses and specific diagnoses, alongside mortality for specific mental disorders.<h3>Methods</h3>For this large-scale random-effects meta-analysis, we searched PubMed, PsycINFO, Embase, Scopus, African Index Medicus, and LILACS from database inception to April 6, 2025, for prospective or retrospective cohort studies published in English. We included studies reporting on patients with schizophrenia spectrum disorder, bipolar disorder, major depressive disorder or depressive episodes, or mixed severe mental illness (defined as at least two among bipolar, depressive, and schizophrenia spectrum disorders). Publications had to include a control group from the general population and quantified reporting. We excluded cross-sectional studies, reviews, systematic reviews, and meta-analyses; studies that did not have respiratory-related mortality data; studies of clustered mixed groups that did not have at least 70% of the patient sample corresponding to our diagnoses, or studies in which the data were not suitable for meta-analysis. The primary outcome was adjusted risk ratio (RR) of overall respiratory disease-related mortality in people with severe mental illness (both pooled and for the specific severe mental disorders) versus the general population control group. Two authors extracted the data using a predetermined data extraction form. The information extracted included first author, country, setting (inpatient, outpatient, or both), data source, design of the study (prospective or retrospective), number of participants and their demographics (sex and mean age), specific severe mental illness and respiratory disease diagnosis, and the RR mortality of each respiratory disease. We assessed the risk of bias in each study using the Newcastle–Ottawa scale and heterogeneity was assessed with a multilevel random-effects meta regression. Individuals with lived experience of mental illness were not involved in the design, analysis, or dissemination of this study. The study was conducted in accordance with PRISMA and was registered with PROSPERO (CRD42024563552).<h3>Findings</h3>Our search identified 83 studies that met the eligibility criteria. We included 4 837 720 people with pooled severe mental illness (2 383 821 males [49·3%] and 2 453 899 females [50·7%]; mean age 57·7 years [SD 13·5]). Data on ethnicity or race were insufficiently reported to be included in our study. Our control group comprised 785 538 236 individuals from the general population (382 185 432 [48·7%] males and 403 352 804 [51·3%] females). 57 studies included peopl
与一般人群相比,患有严重精神疾病的人的预期寿命减少了10-20年。呼吸系统疾病是这种过早死亡的主要原因,但没有对这一人群的总体和呼吸系统原因特异性死亡风险进行全面的荟萃分析。我们的目的是评估患有严重精神疾病和特定诊断的特定呼吸系统疾病患者的死亡率,以及特定精神障碍的死亡率。方法在这项大规模随机效应荟萃分析中,我们检索了PubMed、PsycINFO、Embase、Scopus、African Index Medicus和LILACS从数据库建立到2025年4月6日发表的英文前瞻性或回顾性队列研究。我们纳入了报告精神分裂症谱系障碍、双相情感障碍、重度抑郁症或抑郁发作、或混合严重精神疾病(定义为双相情感障碍、抑郁症和精神分裂症谱系障碍中至少两种)患者的研究。出版物必须包括来自一般人群的控制组和量化报告。我们排除了横断面研究、综述、系统综述和荟萃分析;没有呼吸相关死亡率数据的研究;聚集性混合组的研究中,至少有70%的患者样本不符合我们的诊断,或者数据不适合荟萃分析的研究。主要结局是严重精神疾病患者(包括合并和特定严重精神障碍)与一般人群对照组的总体呼吸系统疾病相关死亡率的调整风险比(RR)。两位作者使用预定的数据提取表单提取数据。提取的信息包括第一作者、国家、环境(住院、门诊或两者都有)、数据来源、研究设计(前瞻性或回顾性)、参与者人数及其人口统计学(性别和平均年龄)、特定的严重精神疾病和呼吸系统疾病诊断,以及每种呼吸系统疾病的RR死亡率。我们使用纽卡斯尔-渥太华量表评估每项研究的偏倚风险,并使用多水平随机效应meta回归评估异质性。有精神疾病生活经历的个体没有参与本研究的设计、分析或传播。该研究按照PRISMA进行,并在PROSPERO注册(CRD42024563552)。我们检索了83项符合资格标准的研究。共纳入4 837720例合并严重精神疾病患者,其中男性2 383 821例(49.3%),女性2 453 899例(50.7%),平均年龄57.7岁(SD 13.5)。关于民族或种族的数据未被充分报道纳入我们的研究。对照组来自普通人群785 538 236人,其中男性382 185 432人(48.7%),女性403 352 804人(51.3%)。57项研究纳入了精神分裂症谱系障碍患者(2979 ~ 972);21例包括双相情感障碍患者(491758例);20例包括重度抑郁症患者(1 327 642例);10项研究包括患有混合严重精神疾病的个体(968326)。在所有83项研究中,与一般人群相比,合并严重精神疾病与呼吸相关死亡率显著升高相关(RR 2.28 [95% CI 2.02 - 2·56])。与一般人群相比,精神分裂症谱系障碍患者的呼吸相关死亡率最高(RR为2.60[2.28 - 2.96],来自57项研究),其次是双相情感障碍(RR为1.96[1.57 - 2.43],来自21项研究)、混合严重精神疾病(RR为1.91[1.43 - 2.54],来自10项研究)和重度抑郁症(RR为1.72[1.39 - 2.13],来自20项研究)。在质量评价中,平均得分为8.7分(满分9分)。78项纳入的研究(94%)被评为质量良好(纽卡斯尔-渥太华评分为7-9分),5项研究(6%)被评为质量一般(5-6分)。综合严重精神疾病和特定严重精神疾病患者的总体和特定呼吸系统疾病死亡风险显著高于普通人群。应制定和实施戒烟、肺癌筛查、呼吸道感染疫苗接种和严重精神疾病患者肺部健康监测规划,以解决这一人群未得到满足的健康需求。欧盟卡洛斯三世基金研究所。
{"title":"Mortality from respiratory diseases in individuals with severe mental illness: a large-scale systematic review and meta-analysis of pooled and specific diagnoses","authors":"David Laguna-Muñoz, María P Pata, Ana Jiménez-Peinado, María José Jaén-Moreno, Cristina Camacho-Rodríguez, Gloria Isabel del Pozo, Eduard Vieta, Christoph U Correll, Marco Solmi, Javier Caballero-Villarraso, María Isabel Alarcón-Laguna, Fernando Sarramea","doi":"10.1016/s2215-0366(25)00262-7","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00262-7","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;People with severe mental illness have a 10–20 year reduced life-expectancy compared with the general population. Respiratory diseases are a main cause of this premature mortality, but no comprehensive meta-analysis of overall and respiratory cause-specific mortality risk in this population exists. We aimed to evaluate the mortality from specific respiratory diseases for people with pooled severe mental illnesses and specific diagnoses, alongside mortality for specific mental disorders.&lt;h3&gt;Methods&lt;/h3&gt;For this large-scale random-effects meta-analysis, we searched PubMed, PsycINFO, Embase, Scopus, African Index Medicus, and LILACS from database inception to April 6, 2025, for prospective or retrospective cohort studies published in English. We included studies reporting on patients with schizophrenia spectrum disorder, bipolar disorder, major depressive disorder or depressive episodes, or mixed severe mental illness (defined as at least two among bipolar, depressive, and schizophrenia spectrum disorders). Publications had to include a control group from the general population and quantified reporting. We excluded cross-sectional studies, reviews, systematic reviews, and meta-analyses; studies that did not have respiratory-related mortality data; studies of clustered mixed groups that did not have at least 70% of the patient sample corresponding to our diagnoses, or studies in which the data were not suitable for meta-analysis. The primary outcome was adjusted risk ratio (RR) of overall respiratory disease-related mortality in people with severe mental illness (both pooled and for the specific severe mental disorders) versus the general population control group. Two authors extracted the data using a predetermined data extraction form. The information extracted included first author, country, setting (inpatient, outpatient, or both), data source, design of the study (prospective or retrospective), number of participants and their demographics (sex and mean age), specific severe mental illness and respiratory disease diagnosis, and the RR mortality of each respiratory disease. We assessed the risk of bias in each study using the Newcastle–Ottawa scale and heterogeneity was assessed with a multilevel random-effects meta regression. Individuals with lived experience of mental illness were not involved in the design, analysis, or dissemination of this study. The study was conducted in accordance with PRISMA and was registered with PROSPERO (CRD42024563552).&lt;h3&gt;Findings&lt;/h3&gt;Our search identified 83 studies that met the eligibility criteria. We included 4 837 720 people with pooled severe mental illness (2 383 821 males [49·3%] and 2 453 899 females [50·7%]; mean age 57·7 years [SD 13·5]). Data on ethnicity or race were insufficiently reported to be included in our study. Our control group comprised 785 538 236 individuals from the general population (382 185 432 [48·7%] males and 403 352 804 [51·3%] females). 57 studies included peopl","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"21 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Climate change and mental health: announcing a new Lancet Psychiatry Commission 气候变化与心理健康:宣布成立新的《柳叶刀》精神病学委员会
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-10 DOI: 10.1016/s2215-0366(25)00274-3
Lasse Brandt, Jura Augustinavicius, Paolo Fusar-Poli, Alkomiet Hasan, Vikram H Patel, Judit Simon, Jurjen J Luykx
No Abstract
没有抽象的
{"title":"Climate change and mental health: announcing a new Lancet Psychiatry Commission","authors":"Lasse Brandt, Jura Augustinavicius, Paolo Fusar-Poli, Alkomiet Hasan, Vikram H Patel, Judit Simon, Jurjen J Luykx","doi":"10.1016/s2215-0366(25)00274-3","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00274-3","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"50 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large language models as mental health providers 作为心理健康提供者的大型语言模型
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-09 DOI: 10.1016/s2215-0366(25)00269-x
Tony Rousmaniere, Simon B Goldberg, John Torous
No Abstract
没有抽象的
{"title":"Large language models as mental health providers","authors":"Tony Rousmaniere, Simon B Goldberg, John Torous","doi":"10.1016/s2215-0366(25)00269-x","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00269-x","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"34 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital trauma: deepfake victimisation and AI-generated violence 数字创伤:深度受害和人工智能引发的暴力
IF 64.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-09-09 DOI: 10.1016/s2215-0366(25)00275-5
Muhammad Umar
No Abstract
没有抽象的
{"title":"Digital trauma: deepfake victimisation and AI-generated violence","authors":"Muhammad Umar","doi":"10.1016/s2215-0366(25)00275-5","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00275-5","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"3 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Psychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1